Clinical Trials Logo

Filter by:
NCT ID: NCT05695261 Not yet recruiting - Food Allergy Clinical Trials

Evaluating the Safety and Efficacy of Oral Encapsulated Microbiota Transplantation Therapy in Peanut Allergic Patients.

Start date: February 15, 2023
Phase: Phase 2
Study type: Interventional

This is a phase II randomized double-blind placebo-controlled trial that aims at evaluating the safety and tolerability of oral encapsulated fecal microbial transplantation therapy (MTT) in peanut allergic patients. In this research the investigators would like to learn more about ways to treat peanut allergies. The primary objective is to evaluate whether MTT with antibiotic pretreatment can increase the threshold of peanut reactivity during a double-blind placebo-controlled food challenge from <=100 mg peanut protein to 300 mg after 28 days of MTT /placebo therapy and 4 months post therapy initiation.

NCT ID: NCT05695209 Not yet recruiting - Depression Clinical Trials

Equity Using Interventions for Pain and Depression - Pilot Randomized Controlled Trial

EQUIPD-Pilot
Start date: April 2023
Phase: N/A
Study type: Interventional

This project is part of the NIH Helping to End Addiction Long-term (HEAL) initiative (https://heal.nih.gov/). This pilot randomized controlled trial (RCT) is part of phase 1 of a two-phase, 5-year project with the overarching goal of testing a decision aid (DA)/coaching intervention, tailored to Black patients with comorbid chronic pain and depression, to encourage use of and adherence to nonpharmacological pain treatments (NPTs). This 2-arm pilot trial will aim to enroll up to 40 Black patients with comorbid chronic musculoskeletal pain and depression in primary care from an urban safety-net health system with the end goal of at least 30 patients completing the trial. After the baseline assessment, patients randomized to the intervention will be asked to participate in 4 coaching sessions over approximately 12 weeks. Sessions will use Motivational Interviewing principles to foster openness to NPTs and self-efficacy by helping patients identify their goals and priorities, understand their NPT options, prepare them to discuss and choose options with their primary care providers (PCPs), and reinforce these choices to foster maintenance of these changes. DA contents will be integrated into these sessions, which will facilitate discussion of these options with their PCP. The first 3 sessions take place prior to the patient's next scheduled PCP visit; the final session occurs after this visit. Assessments will be conducted at baseline, 3 months (i.e., after completing the final coaching session), and 6 months. Patients randomized to the wait-list control group will receive usual care (in addition to study assessments at baseline, 3 months, and 6 months). After completing the final assessment, they will then be given the DA along with a 20-minute coaching session to walk them through it (patients may decline the coaching session or schedule for a future time).

NCT ID: NCT05695196 Not yet recruiting - Clinical trials for Microbial Colonization

Parent-to-Child Nasal Microbiota Transplant to Promote Colonization Resistance to Staphylococcus Aureus

Start date: May 1, 2023
Phase: Phase 1
Study type: Interventional

This pilot study looks to determine whether transferring a parents healthy, diverse nasal microbiota to the participant's infant(s) will create a healthy, diverse neonatal nasal microbiome.

NCT ID: NCT05695183 Not yet recruiting - Intravenous Access Clinical Trials

IV SafeLock Device Functionality in Emergency Department

Start date: May 1, 2023
Phase: N/A
Study type: Interventional

The purpose of this research study is to evaluate the functionality of the IV SafeLock in the clinical emergency department setting.

NCT ID: NCT05695170 Recruiting - Clinical trials for Overweight and Obesity

Couple-Based Lifestyle Intervention to Prevent Type 2 Diabetes

Start date: December 14, 2022
Phase: N/A
Study type: Interventional

The goal of this randomized pilot clinical trial is to describe the feasibility of a couple-based lifestyle intervention and the study protocol in preparation for a future definitive randomized clinical trial. Participants include individuals at risk for type 2 diabetes and their romantic partners. The main objectives are: 1. To describe the feasibility of the couple-based intervention. 2. To describe the feasibility of the study protocol for use in a definitive trial. Participating couples will be randomized to one of two year-long lifestyle intervention conditions: an individual curriculum or a couple-based curriculum. Participants will complete assessments before and after the year-long intervention, as well as monthly during the intervention. Data will be collected on: feasibility, background, health behaviors, physical and mental health, and relationship functioning.

NCT ID: NCT05695105 Not yet recruiting - Dental Ankylosis Clinical Trials

Novel Treatment for Dental Ankylosis

Start date: March 2023
Phase: N/A
Study type: Interventional

The study is to determine whether one (or two) new method(s) will help treat dental ankylosis. This study tackles the challenging tooth-bone fusion disorder of ankylosis. In growing patients, ankylosis causes significant developmental bone defects due to its inhibition of the vertical growth of the affected alveolar bone area.

NCT ID: NCT05695027 Recruiting - Clinical trials for Primary Open Angle Glaucoma

Nicotinamide and Pyruvate for Open Angle Glaucoma: A Randomized Clinical Study

Start date: January 15, 2023
Phase: Phase 2/Phase 3
Study type: Interventional

The objective of this study is to determine if a combination of oral nicotinamide and pyruvate (N&P) can maintain eye health as compared to placebo while standard-of-care intraocular pressure-lowering glaucoma medications are used to treat glaucoma.

NCT ID: NCT05694884 Recruiting - Atopic Dermatitis Clinical Trials

Study of Eblasakimab in Male or Female Moderate-to-Severe Atopic Dermatitis Patients Previously Treated With Dupilumab

Start date: December 21, 2022
Phase: Phase 2
Study type: Interventional

Multicenter, randomized, double-blind, placebo-controlled, parallel arm clinical study designed to evaluate the efficacy and safety of eblasakimab in participants with moderate-to-severe atopic dermatitis (AD) previously treated with dupilumab.The study consists of a 16-week treatment period and an 8-week follow-up period up to Week 24. Eligible participants will be randomized into one of the 2 treatment arms.

NCT ID: NCT05694832 Not yet recruiting - Clinical trials for Graft Versus Host Disease

Expressive Writing in GVHD

EXPRESS-C-GVHD
Start date: February 1, 2023
Phase: Early Phase 1
Study type: Interventional

Graft-versus-host-disease (GVHD) is a disease phenomenon that occurs when immune cells of the donor recognize and attack healthy tissue within the transplant recipient, or host. It is ultimately the result of the same immunological mechanisms that provide benefit to patients receiving hematopoietic stem cell transplantation (HSCT). In patients with hematologic malignancies, HSCT can be therapeutic, as donor T cells recognize and mount a response against cancerous cells. HSCT is also used in the setting of certain immunodeficiencies and inborn errors of metabolism for which therapeutic benefit is found in immunologic repletion. To our knowledge, support groups have yet to be investigated in academic literature as a nonpharmacologic, therapeutic intervention for cutaneous GVHD patients to improve their distress, systemic disease, and quality of life. Given the dearth of research on nonpharmacologic therapies for cutaneous GVHD that address quality of life impairments, we seek to characterize the effect of an expressive writing and peer helping intervention contextualized within the framework of a support group. The primary goal of this study is to provide preliminary efficacy data of expressive writing as an intervention in patients with cutaneous GVHD to trial.

NCT ID: NCT05694741 Recruiting - Type 2 Diabetes Clinical Trials

A Study to Assess Safety, Tolerability, and Pharmacokinetics of AZD0186

Start date: December 20, 2022
Phase: Phase 1
Study type: Interventional

This study will assess the safety, tolerability, and pharmacokinetics of AZD0186 following single ascending doses (SAD) via oral administration in healthy adult participants.